ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ NGƯỜI BỆNH U LYMPHO TẾ BÀO T/NK NGOÀI HẠCH BẰNG PHÁC ĐỒ SMILE TẠI BỆNH VIỆN CHỢ RẪY

Objective: To describe the clinical and biological characteristics, the complications related to the treatment, and the treatment response of extranodal NK/T cell lymphoma (ENKL) patients treated with the SMILE regimen (steroid, methotrexate, ifosfamide, L-asparaginase/pegaspargase and etoposide) at Cho Ray Hospital.Subjects and methods: A retrospective case series study was conducted at the Department of Hematology, Cho Ray Hospital, from January 2021 to May 2026. Clinical, biological, and treatment characteristics of ENKL patients treated with the SMILE regimen were collected from the electronic medical record software and patient records. Efficacy was assessed according to the Lugano 2014 criteria based on PET/CT scans combined with re-biopsy of suspicious lesions.Results: From January 2021 to May 2026, we collected information on 31 ENKL patients who met the study criteria. The mean age was 44.7 ± 10 years, and the male:female ratio was 2.44:1. The percentages of patients with nasal congestion, facial swelling and B symptoms were 29%, 12.9%, and 45.2%, respectively. Lugano stage IV accounted for 38.7%, and high risk according to PINK-E for 19.4%. Sixteen patients were treated with the modified SMILE regimen. Among the 14 patients evaluated for response after 3 cycles of chemotherapy, the overall response rate and complete response rate were 92.9% and 78.6%, respectively. The most common complication was grade 4 neutropenia, accounting for 93.1%, followed by elevated liver enzymes and hypokalemia, accounting for 90.3% and 76.9%, respectively. With a median follow-up of 12.8 months, the mortality rate was 35.5% (11/31), mainly due to septic shock during bone marrow suppression after chemotherapy.Conclusion: The SMILE regimen for ENKL patients at Cho Ray Hospital achieved promising response rates in patients evaluated for response; however, hematologic toxicity and infection-related death during bone marrow suppression after chemotherapy remain major challenges.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine Bach Mai Hospital
Published
2026-11-21
DOI
https://doi.org/10.52322/jocmbmh.156.0314
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ NGƯỜI BỆNH U LYMPHO TẾ BÀO T/NK NGOÀI HẠCH BẰNG PHÁC ĐỒ SMILE TẠI BỆNH VIỆN CHỢ RẪY

Hoang Thi Thuy Ha, Thái Minh Hiếu Lý, Dương Bích Trâm Huỳnh
Journal of Clinical Medicine Bach Mai Hospital
Lymphoma Diagnosis and Treatment
article

ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ NGƯỜI BỆNH U LYMPHO TẾ BÀO T/NK NGOÀI HẠCH BẰNG PHÁC ĐỒ SMILE TẠI BỆNH VIỆN CHỢ RẪY

Hoang Thi Thuy Ha, Thái Minh Hiếu Lý, Dương Bích Trâm Huỳnh
article en

Abstract

Objective: To describe the clinical and biological characteristics, the complications related to the treatment, and the treatment response of extranodal NK/T cell lymphoma (ENKL) patients treated with the SMILE regimen (steroid, methotrexate, ifosfamide, L-asparaginase/pegaspargase and etoposide) at Cho Ray Hospital.Subjects and methods: A retrospective case series study was conducted at the Department of Hematology, Cho Ray Hospital, from January 2021 to May 2026. Clinical, biological, and treatment characteristics of ENKL patients treated with the SMILE regimen were collected from the electronic medical record software and patient records. Efficacy was assessed according to the Lugano 2014 criteria based on PET/CT scans combined with re-biopsy of suspicious lesions.Results: From January 2021 to May 2026, we collected information on 31 ENKL patients who met the study criteria. The mean age was 44.7 ± 10 years, and the male:female ratio was 2.44:1. The percentages of patients with nasal congestion, facial swelling and B symptoms were 29%, 12.9%, and 45.2%, respectively. Lugano stage IV accounted for 38.7%, and high risk according to PINK-E for 19.4%. Sixteen patients were treated with the modified SMILE regimen. Among the 14 patients evaluated for response after 3 cycles of chemotherapy, the overall response rate and complete response rate were 92.9% and 78.6%, respectively. The most common complication was grade 4 neutropenia, accounting for 93.1%, followed by elevated liver enzymes and hypokalemia, accounting for 90.3% and 76.9%, respectively. With a median follow-up of 12.8 months, the mortality rate was 35.5% (11/31), mainly due to septic shock during bone marrow suppression after chemotherapy.Conclusion: The SMILE regimen for ENKL patients at Cho Ray Hospital achieved promising response rates in patients evaluated for response; however, hematologic toxicity and infection-related death during bone marrow suppression after chemotherapy remain major challenges.

Journal of Clinical Medicine Bach Mai HospitalVol. 3(156)
Cho Ray Hospital (VN)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ NGƯỜI BỆNH U LYMPHO TẾ BÀO T/NK NGOÀI HẠCH BẰNG PHÁC ĐỒ SMILE TẠI BỆNH VIỆN CHỢ RẪY — Hoang Thi Thuy Ha, Thái Minh Hiếu Lý, et al. · Journal of Clinical Medicine Bach Mai Hospital (2026) | TGRS Research Map | TGRS